fever/diarrhea

BACKGROUND OF THE INVENTION The invention relates generally to the use of sesquiterpene lactones in the treatment of infections caused by Flaviviridae and, more specifically, to the use of sesquiterpene lactone endoperoxides to treat hepatitis C infections, yellow fever, dengue fever, bovine viral

SEQUENCE LISTING The instant application containa a sequence listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 13,2011 is named X19558_ST25.txt and is 4,567 bytes in size. STATEMENT REGARDING

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to the isolation and characterization of novel Classical Swine Fever Virus (CSFV) virulence determinants within the E2 structural glycoprotein and utilization of these novel virulence determinants to design live attenuated

BACKGROUND OF THE INVENTION The present invention relates to the treatment of certain conditions using a compound of formula I or II, or a pharmaceutically acceptable salt thereof, as defined below. Specifically, the compounds of formulas I and II, and their pharmaceutically acceptable salts, as

FIELD OF THE INVENTION This invention is directed to novel compounds which are useful in the treatment of viral infections. The invention is also directed to pharmaceutical compositions containing the compounds, processes for their preparation and uses of the compounds in various medicinal

FIELD OF THE INVENTION This invention is directed to novel compounds which are useful in the treatment of viral infections. The invention is also directed to pharmaceutical compositions containing the compounds, processes for their preparation and uses of the compounds in various medicinal

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not Applicable. BACKGROUND The unstable nature of the RNA molecule enables RNA viruses to evolve far more rapidly than DNA viruses, frequently changing their surface structures. RNA viruses in general have very high mutation rates as

FIELD OF THE INVENTION The present invention is directed to attenuated pestivirus mutants, which have a reduced ability to replicate, which is exhibited by a small plaque size. Such viruses are useful as live vaccines in the control of bovine viral diarrhea, classical swine fever and border disease

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to Shigella vaccine, strains, their use in vaccines, and the methods for treatment of dysentery. 2. Related Art Shigella spp. is the causative agent of bacillary dysentery. The distal end of the colon and

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to Shigella vaccine, strains, their use in vaccines, and the methods for treatment of dysentery. 2. Related Art Shigella spp. is the causative agent of bacillary dysentery. The distal end of the colon and